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peritoneal dialysis with spironolactone
César A. Restrepo Valencia1, Gilberto Manjarrés Iglesias1-2, Consuelo Vélez Álvarez3
Abstract
Objective: To determine whether a treatment with spironolactone can correct chronic idiopathic hypokale-
mia for patients with chronic kidney disease undergoing treatment with peritoneal dialysis.
Design: Interventional study without control group.
Patients: Patients with chronic kidney disease over 18 years old, undergoing treatment with peritoneal 
dialysis for over 1 year; with reported diuresis of less than 100 ml in 24 hours and in whom chronic idiopathic 
hypokalemia was diagnosed.
Materials and methods: All patients were tested for known causes of hypokalemia; once these causes 
were discarded we initiated treatment with spironolactone with an initial dose of 25 mgs per day and a mon-
thly increase of 25 mgs until a maximum dose of 200 mg per day. Serum potassium was measured monthly 
and dialyzed potassium was measured every 6 months.
Results: 20 patients fulfilled the requirements for inclusion. Four patients (20%) developed hyperkalemia 
and had to stop the treatment. For the remaining 16 patients initial potassium of 2,84 was measured, 6 months 
later it was elevated to 3,40; 3,37 after 12 months; 3,58 after 18 months and 3,9 after 22 months, these values 
were statistically significant (p < 0,05). 12 episodes of peritonitis occurred for the 16 patients, representing an 
incidence of 1 episode per 19 patients month. The average dose of spironolactone used after 3 months was 65 
mgs; 67 mgs after 6 months; 75 mgs after 12 months; 60 mgs after 18 months and 68 mgs after 22 months. 
In the 22 months follow up, 5 (25%) patients were with drawn for motives not related to therapy and 7 of the 
16 (43.75%) patients passed away.
Conclusions: Hypokalemia is a cause of great mortality for patients undergoing treatment with peritoneal 
dialysis; in addition to its own risks it also facilitates the development of peritonitis that requires additional 
therapeutic interventions. We suggest that could Spironolactone diminish the intestinal loss of potassium but 
may cause hyperkalemia so patients must be closely monitored.
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Resultados del tratamiento de la hipopotasemia con espironolactona en paciente con 
enfermedad renal crónica en dialisis peritoneal
Resumen
Objetivo: Determinar si el tratamiento con espironolactona puede corregir la hipopotasemia crónica idiopá-
tica de pacientes con enfermedad renal crónica (ERC) en tratamiento con diálisis peritoneal.
Diseño: Estudio de intervención sin grupo control.
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Pacientes: Pacientes con ERC mayores de 18 años, quienes requirieron diálisis peritoneal por más de 1, 
quienes tenían una diuresis menor a 100 ml/24 horas, y en quienes se había diagnosticado hipopotasemia 
crónica idiopática.
Materiales y metodos: Todos los pacientes fueron valorados para causas conocidas de hipopotasemia. 
Una vez que fueron descartadas se optó por iniciar tratamiento con espironolactona, a una dosis inicial de 25 
mgs por día e incrementos mensuales de 25 mgs, hasta una dosis máxima de 200 mgs. El potasio sérico fue 
medido cada mes y el potasio del dializado cada 6 meses.
Resultados: 20 pacientes cumplieron con los criterios de inclusión. 4 pacientes (20%) desarrollaron hiper-
potasemia y requirieron suspensión del tratamiento. Para el resto de los 16 pacientes el potasio inicial fue de 
2,84 y 6 meses más tarde se elevó a 3,40; a los 12 meses su valor fue de 3,37, 3,58 a los 18 meses y 3,9 a los 
22 meses, valores que fueron estadísticamente significativos (p < 0,05). Se presentaron en el seguimiento de 
los 16 pacientes 12 episodios de peritonitis con una incidencia de 1 episodio por 19 pacientes mes. La dosis 
promedio de espironolactona utilizada fue de 65, 67, 75, 60 y 68 mgs para los meses 3, 6, 12, 18 y 22, respec-
tivamente, de seguimiento. 5 pacientes (25%) fueron retirados del seguimiento por motivos no relacionados 
con la terapia y 7 pacientes (43,75%) fallecieron.
Conclusiones: La hipopotasemia es causal de mortalidad en pacientes en tratamiento con diálisis perito-
neal. Además su presencia es un factor de riesgo para la aparición de peritonitis, la cual requiere interven-
ciones adicionales. Nosotros sugerimos que la espironolactona puede disminuir las pérdidas intestinales de 
potasio, pero puede causar hiperpotasemia, siendo importante el seguimiento estrecho de los pacientes bajo 
tratamiento.
Palabras clave: Enfermedad renal crónica, diálisis peritoneal, hipopotasemia (MeSHsource).
Introduction
Hypokalemia is a complication rarely repor-ted in patients with chronic kidney disease (CKD) although its prevalence can fluctuate 
between 10% through 36% in reports from several 
studies1,2. Its etiology has been attributed to several 
different factors: some of them related to the under-
lying disease; others, to medical therapies, malnutri-
tion and diets with low potassium intake3. Another 
explanation blames the transcelular distribution of 
potassium stimulated by insulin (in response to pe-
ritoneal glucose)4, loss of potassium through urine, 
sweat and peritoneum specially when the number 
of exchanges is high and residual kidney function 
is presented5. In a few patients the etiology is idio-
pathic; we believe the intestinal loss of potassium 
may be an important cause due to the stimulation of 
the intestinal receptor by mineralocorticoid activity. 
It is our belief that blocking these receptors could 
prove beneficial for restoring the levels of potassium 
to normal.
This study describes our experience using spirono-
lactone for the management of hypokalemia in chro-
nic kidney disease patients undergoing peritoneal 
dialysis.
Patients, materials and methods
Patients with chronic kidney disease over 18 years 
old, undergoing treatment with peritoneal dialysis for 
over 1 year; with reported diuresis of less than 100ml 
in 24 hours and in whom chronic idiopathic hypokale-
mia (more than 4 months evolution) was diagnosed.
Hypokalemia was defined as values lower than 
3,5mEq/L. Demographic variables were analyzed 
and all patients were evaluated for initial KT/V and 
Test of Peritoneal Equilibrium. These variables were 
also analyzed at the end of the study and the last re-
gistered value was used for the patients who passed 
away or were removed from treatment due to hyper-
kalemia or other reasons.
A high potassium intake diet was implemented in all 
patients; explainable causes of hypokalemia were 
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discarded such as chronic diarrheal syndrome, repe-
tition emesis, excessive sweating, excessive minera-
locorticoids and the intake of medications than can 
cause hypokalemia (Diuretics, B2 adrenergics and 
xantines). We added an angiotensin converting en-
zyme inhibitor (ACE inhibitor) or an angiotensin II 
receptor antagonist (ARBs) to the treatment for all 
patients without low blood pressure values. Blood 
pressure was registered monthly and for its control 
in case high values were found an ACE inhibitor or 
an ARB was added in the first place, followed by a 
calcium channel blocker or an Alfa 1 antagonist de-
pending on the treating doctors' judgment; the goal 
blood pressure was set around 140/90mmHg.
The levels for renin and aldosterone were determi-
ned for all patients as well as the dialyzed 24 hours 
potassium excretion. 24 hour potassium in urine was 
not determined due to the fact that all patients were 
anuric (diuresis less tan 100ml/24 hours); 24 hours 
fecal potassium was not determined either due to the 
difficulties at obtaining and processing the samples. 
Patients received spironolactone with an initial dose 
of 25 mg per day and a monthly increase of 25 mg 
until a maximum dose of 200 mgs per day. In case a 
potassium level was found higher than 4,5meq/L the 
dose was reduced by 25 mgs; higher than 5,0meq/L 
it was reduced by 50 mgs and if it was found higher 
tan 5,5meq/L the treatment was suspended. Serum 
potassium was measured monthly and dialyzed po-
tassium was measured every 6 months. The study 
was extended for 22 months for the patients who 
achieved the time of evaluation, corresponding to 
the last cut of the research data.
Design
Interventional study without a control group. All pa-
tients gave their written consent before taking part 
in the study.
Results
20 patients met the inclusion criteria, 12 (60%) in 
CAPD program and 8 (40%) in APD. 4 men and 16 
women with a mean age of: 65.7 +/- 9.08, CKD etio-
logy: 12 (60%) diabetic nephropathy, 4 (20%) hyper-
tensive nephropathy, 4 (20%) unknown etiology.
Four (20%) patients required the discontinuation 
of therapy due to the appearance of hyperkalemia 
(mean plasma potassium at suspension of 5.905 +/- 
0.34 mEq/L) without clinical or electrocardiogra-
phic changes; all within the first 9 months of thera-
py and an average of 5.25 months; with an average 
dose of spironolactone at the time of suspension of 
31.25 +/- 12.5 mg. Interestingly during the 14 mon-
ths follow up of this group, no patient passed away 
or presented hypokalemia.The age of these patients 
was 65.25 +/- 8.42 years, while the group that did 
not present 65.81 +/- 9.50 without statistically signi-
ficant differences.
Of 16 (80%) patients who did not develop hyper-
kalemia, eleven completed 6 months follow-up, 8 
twelve months, six 17 months, and only four pa-
tients 22 months.
5 patients were withdrawn for reasons unrelated to 
therapy: two were transferred to a different health 
institution, one underwent renal transplant, one had 
a recovering residual renal function and one was 
transferred to hemodialysis due to refractory peri-
tonitis. 7 of the 16 (43.75%) patients passed away 
during follow-up; their average serum potassium at 
the time of death was 3.06 +/- 0.70. 2 within the first 
4 months of starting treatment; the causes of death 
were: 1 myocardial infarction and 1 pneumonia; the 
remaining 5 patients passed away between three and 
seven months of treatment; one at 11 months and the 
last at 16 months. The causes of death were: 2 he-
morrhagic strokes, 2 lower limb gangrene, and one 
sudden death.
Only 3 patients’ had initial potassium values higher 
than 30 mEq in 24 hours dialysate; two of them pas-
sed away in the first 6 months follow-up. The remai-
ning patient had a potassium dialysate of 31.58 at 6 
months treatment; 35.88 at 12 months; 43.74 at 18 
months and 15.7 at 22 months. The 24 hours dialy-
sate potassium was found at an average of 26.78 +/- 
15.22 for all patients; an average of 26.40 +/- 16.17 
for the patients who didn't develop hyperkalemia, 
and an average of 28.32 +/- 12.78 for the ones who 
did present it. At 6 months follow up this value was 
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32.51 +/- 10.82 for all patients; 30.19+/- 10.63 for 
the group without hyperkalemia and an elevation 
was found in the hyperkalemia group with an ave-
rage of 42.92+/- 2.90. This probably reflected serum 
potassium and indicated dialysate independent fac-
tors in the generation of changes in serum potas-
sium. The 12 month follow up values for the group 
without hyperkalemia were averages of: 22.51 +/- 
5.44 at 12 months; 30.91 +/- 12.87 at 18 months and 
29.93 +/- 18.48 at 22 months.
The initial serum albumin was evaluated for an ave-
rage of 3.15 +/- 0.39 for all patients; for deceased 
patients an average of 2.99 +/- 0.51 and for non de-
ceased patients an average of (13) 3.25 +/- 0.30. Of 
the 7 patients who passed away six (85.71%) had 
low albumin values at baseline. The initial serum 
albumin for patients who developed hyperkalemia 
during treatment was an average of 3.45 +/- 0.05 and 
for those who didn't it was an average of 3.09 +/- 
0.41.In the group of patients with improvement in 
the value of serum potassium, serum albumin from 
an initial value of 3.09 +/- 0.41 shifts to a final value 
of 3.09 +/- 0.54 statistically unchanged significant.
The total values of renin before treatment averaged 
22.33 pg/ml; the total values for aldosterone ave-
raged 6.51 ng/100 cc. No patient presented renin 
values greater than 65 pg/ml; or aldosterone values 
greater than 20 ng/100cc compatible with mineralo-
corticoid excess.
12 episodes of peritonitis occurred in 16 patients, 
representing an incidence of 1 episode per 19 pa-
tients month; in comparison with the total group of 
patients (136 on average) evaluated in the same time 
period and with a calculated incidence of 1 episode 
per 44 patients month.
The initial potassium for the 16 patients who didn't 
develop hyperkalemia was 2.84; at 6 months it was 
raised to 3.40; at 12 months 3.37; 18 months 3.58 
and at 22 months it was 3.9 (Figure 1). The avera-
ge dose of spironolactone used at 3 months was 65 
mgs; 67 mgs at 6 months; 75 mgs at 12 months; 60 
mgs at 18 months, 68 mgs at 22 months.
In order to the determine the behavior of serum po-
tassium in the patients enrolled in the study we used 
the following procedure. Patients who could recei-
Figure 1.
Evolution of serum potassium in time
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ve the 5 measurements (4 patients) were selected 
and their mean result was obtained for each period: 
month 0, month 6, month 12, month 18, and month 
22 (Table 1). When Applying the Normality test we 
found that at month 0 the distribution did not behave 
normally P <0.05; therefore in order to demonstra-
te statistical significance the nonparametric Krus-
kal-Wallis test was applied. Significant differences 
were found (p= 0,034) in the values of serum po-
tassium comparing the 5 period controls of the pa-
tients who ended the process (Table 2,3). Analyzing 
the measurements in the graph, note that at month 
0 they present the lowest average levels and is the 
period that marks the difference compared with the 
measurement at month 22.
The value for initial KT/V was an average of 1.76 
+/- 0.67 for all patients,with an average age of 65.7 
+/- 9.08and at the end it was 1.79 +/- 0.40. The peri-
toneal equilibrium test was evaluated in the group of 
patients who did not develop hyperkalemia; 6 were 
found to be low transporters of glucose; 9 were high 
transporters of glucose; 6 were low transporters of 
creatinine and 9 were high transporters of creatinine. 
Evaluating these parameters at the end of the study 
we found no significant changes.
Evaluating the blood pressure variable we realized 
it was elevated in both groups with and without 
hyperkalemia but we decided not to consider it as an 
important variable because we allowed changes in 
antihypertensive therapy for patients with high car-
diovascular risk. None of the side effects for spiro-
nolactone were observed such as gynecomasty and 
low blood pressure.
Discussion
Hypokalemia is a rare complication in CKD patients 
but it is associated with significant complications 
with increased morbidity and mortality1,3,6 even 
though all-cause and cardiovascular mortality can be 
higher in the first year of peritoneal dialysis7.
Hypokalemia is also considered a risk factor for pe-
ritonitis in patients undergoing peritoneal dialysis8,9. 
It could be caused by a reduction in gastrointesti-
nal motility, with subsequent bacterial overgrowth 
and trans mural migration of enteric organisms10. It 
could also be a marker of malnutrition, relating to 
alterations in the immune defense mechanisms1,11.
Due to the risk that hypokalemia represents, it's 
treatment is paramount. Various therapies have 
Table 1. 
Mean Serum potassium in patients who completed 
the process
Time Mean Standard Deviation
month 0 2,9000  ,20000
month 6 3,4125  ,16520
month 12 3,4575  ,61092
month 18 3,4275  ,38948
month 22 3,9000  ,28284
Total 3,4195  ,46031
Table 2. 
Normality test
POTASSIUM TIME                          Kolmogorov-Smirnov(a)                                     Shapiro-Wilk
  Statistic gl Sig. Statistic gl Sig.
 month 0 ,441 4 . ,630 4 ,001
 month 6 ,252 4 . ,916 4 ,513
 month 12 ,278 4 . ,942 4 ,666
 month 18 ,258 4 . ,900 4 ,429
 month 22 ,260 4 . ,827 4 ,161
a Correlation of significance of Lilliefors
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been tried; including increased oral intake of potas-
sium2, 12; Icodextrin to improve nutritional status, 
and generate lower insulin secretion13,14; potassium 
infusion in the bags for dialysis15-17and mineralo-
corticoid blockade with mineralocorticoid receptor 
antagonists (MRAs).
Mineralocorticoid blockade has always been consi-
dered high risk in patients with CKD; it has been 
used in patients with CKD and resistant hyperten-
sion. In a group of patients without dialysis Pisoni et 
al obtained therapeutic efficacy, but with the risk of 
generating hyperkalemia, and a fall in the GFR18. In 
patients undergoing dialysis therapy, Xiaoying Ni et 
al achieved a significant reduction in blood pressure, 
but 2 patients required the discontinuation of medi-
cation by the development of hyperkalemia19.
In the Dialysis Outcome Heart Failure Aldactone 
Study (DOHAS), Matsumoto Y, et al in patients un-
dergoing hemodialysis, spironolactone reduced the 
frequency of death or hospitalization for cardio-ce-
rebrovascular events and hyperkalemia was obser-
ved only in 1.9% of patients20.
In patients undergoing peritoneal dialysis with Class 
III and IV heart failure, the spirono lactone improve-
ment the patients' ejection fraction, and left ventricle 
mass index with very low side effects such as hyper-
kalemia, only in one patient in the study of Taheri et 
al21, and 2 in the Ito Y et al22.  
Yongsiri S et al, in a randomized, double-blind, 
placebo controlled trial conducted in 24 peritoneal 
dialysis patients with hypokalemia, evaluated the 
therapeutic response to 25 mgs of spironolactone 
for 4 weeks. They found no significant changes in 
serum potassium; however they did not increase the 
dose and the study was conducted for a very short 
time23.
In our study we found that hypoalbuminemia is com-
mon in patients who were diagnosed with hypokale-
mia, their presence is linked with high mortality 
and the possible emergence of bacterial peritonitis. 
The absence of significant variation in the values of 
serum albumin between its initial and final value ex-
cludes improvement of nutritional status that exp-
lains the rise in serum potassium. 
Treatment with spironolactone can correct hypokale-
mia, but patients must be closely monitored due to 
the risk of hyperkalemia, especially in anuric pa-
tients.The age of patients with treatment in the group 
of hyperkalemia was not different that group without 
hyperkalemia, important aspect because the aged pa-
tients have major possibility of this complication24.
The KT/V and age of the patients at the beginning 
and end of treatment was found in the recommen-
ded goals, being unlikely to contribute to potassium 
disturbances, their correction, and the appearance of 
hyperkalemia.
We suggest that hypokalemic CKD patients under-
going peritoneal dialysis may have an abnormal 
activity in the colon's aldosterone-sensitive epithe-
lial sodium channels, which could result in sodium 
retention and increased potassium loss by diges-
tive tract. We believe that the administration of 
an aldosterone antagonist (spironolactone) could 
reduce their losses and restore serum potassium 
levels.
It has been observed that the aldosterone levels in 
CKD patients rise gradually when their GFR is less 
than 50 ml/minute. The intestinal cells of the colon 
and small intestine may be affected by aldosterone 
effect, with an increase in luminal membrane per-
meability to sodium and a subsequent activation of 
new sodium channels, resulting in an increased acti-
vity and number of Na,K-ATPase pumps. The result 
of the above interaction is intestinal sodium reten-









b Aggregation variable: TIME
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It is also likely that low sodium intake diets com-
mon in CKD patients undergoing dialysis therapy 
may reactively decrease the levels of protein type 
2 11B-hydroxysteroid dehydrogenase (11 B-HSD2) 
in the colon; this protein degrades cortisol to cor-
tisone, a metabolite without sodium retaining acti-
vity. Subsequently an elevation of messenger RNA 
levels occurs and an increased activity of the epi-
thelial sodium channel (ENaC); this condition is 
mediated by the activation of the mineralocorticoid 
receptor26.
In support of our suggestions there are studies that 
have shown that sodium reabsorption is an active 
process that occurs in the rectum and colon muco-
sa27,28. This process is regulated at least in part by 
the mineralocorticoid receptor29 and results in the 
activation of the epithelial sodium channels30. Mine-
ralocorticoid receptor activation by fludrocortisone 
increases the rectal electrical potential difference, an 
effect that is also achieved by inhibiting the enzyme 
11 B-HSD2 in rectal segments obtained from a hu-
man colon31.
The relevance of extra renal 11 B-HSD2 enzymes 
in humans has been demonstrated in patients wi-
thout renal function, in which the glycyrrhetinic 
acid has significantly decreased the levels of plas-
ma potassium32. Colon sodium absorption in expe-
rimental models of chronic renal failure with the 
5/6 nephrectomy, increases as the GFR is reduced, 
accompanied by elevated expression of ENaC, an 
effect that may be partially mediated by the AT1 re-
ceptor agonist33.
Conclusions 
Hypokalemia is a cause of great mortality for pa-
tients undergoing treatment with peritoneal dialysis; 
in addition to its own risks it also facilitates the de-
velopment of peritonitis that requires additional the-
rapeutic interventions. We suggest that the Spirono-
lactone could to correct hypokalemia at diminish the 
intestinal loss of potassium, but may cause hyper-
kalemia so patients must be closely monitored. Pre-
venting malnutrition and avoiding very low sodium 
intake diets may contribute to prevent hypokalemia.
It is necessary to design studio in which can reliably 
measure fecal excretion of potassium, and thus con-
firm our suggestion.
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